系统性硬化症（Systemic sclerosis，SSc），常被称为“硬皮病”，是一种罕见的慢性自身免疫性疾病。它远非简单的皮肤病变，而是以免疫系统紊乱、微血管病变及多器官进行性纤维化为特征，被称为“人体内的水泥病”。 患者皮肤逐渐硬化、紧绷，关节活动受限，更严重的是，肺、心脏、消化道等内脏器官也会因异常纤维化而功能受损，威胁生命。 全球数据显示，该病患病率约为每百万人口50-300例，且女性发 ...

Systemic sclerosis is a complex autoimmune condition marked by aberrant immune activation, widespread fibrosis and vasculopathy that affect the skin and multiple internal organs. The disease manifests ...

Calcinosis cutis, a debilitating deposition of calcium salts in the skin and subcutaneous tissues, is a frequent and challenging complication in patients with systemic sclerosis and other connective ...

Preclinical data showed promise in both systemic sclerosis bleomycin-induced mouse models and in patient-derived skin fibroblasts treated with EYD-001. The Food and Drug Administration (FDA) has ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of ...

A nationwide Swedish register-based study revealed that individuals with systemic sclerosis had a higher risk for hematologic malignancies. Myeloid malignancies typically presented around disease ...

The VEDOSS project has previously shown that 70% of patients with Raynaud's phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on ...

Patients with scleroderma renal crisis demonstrated specific enrichment of CD14+ monocytes with increased EGR1 expression and activation of NF-κB–related pathways. Trajectory analysis indicated that ...

Please provide your email address to receive an email when new articles are posted on . Patients with systemic sclerosis had increased risk for hematologic and solid organ cancers at 5 years vs. a ...

Please provide your email address to receive an email when new articles are posted on . Risks were particularly high in women who received both systemic and local hormone therapies. Future studies ...

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and ...

Opportunities lie in strategic investment formulation, identifying cost-effective locations for conducting trials, understanding global trial trends, and analyzing trial success rates. Insights into ...